<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111056</article-id><article-id pub-id-type="publisher-id">ACM-40155</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_98994631.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  老年II型糖尿病患者血清胱抑素C与心室重构的相关性
  Correlation between Serum Cystatin C and Ventricular Remodeling in Elderly Type 2 Diabetic Patients
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>瑜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苑</surname><given-names>姗姗</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>婷</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>戴</surname><given-names>红艳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属青岛市市立医院，干部保健四科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属青岛市市立医院，门诊部，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>396</fpage><lpage>402</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨老年II型糖尿病患者血清胱抑素C与心室重构的相关性。方法：筛选就诊于我院的老年II型糖尿病患者140例(年龄均 ≥ 65岁)，检测患者血清胱抑素C浓度，根据老年II型糖尿病患者血清胱抑素C浓度，将全部患者分为胱抑素C正常组(胱抑素C ≤ 1.03 mg/L) 60例，胱抑素C升高组(胱抑素C &gt; 1.03 mg/L) 71例。使用超声心动图测量两组患者左室射血分数(left ventricular ejection fraction, EF)、左房内径(left atrial diameter, LAD)、左室舒张末内径(left ventricular end-diastolic diameter, LVD)、左室后壁厚度(left ventricular posterior wall thickness, LVPWT)、室间隔厚度(ventricular septal thickness, IVST)并计算左室质量指数(left ventricular mass index, LVMI)。对这些指标进行组间比较，并分析血清胱抑素C与心室重构的相关性。结果：与胱抑素C正常组相比，胱抑素C升高组的LVMI、IVST显著增高(P &lt; 0.01)。相关分析显示：血清胱抑素C含量与LVMI、IVST呈正相关，并具有统计学意义(P &lt; 0.01)。结论：血清胱抑素C浓度与老年II型糖尿病患者心室重构具有显著相关性，可作为衡量II型糖尿病患者心室重构程度的一项指标。
  Objective: To explore the correlation between serum cystatin C and ventricular remodeling in elderly type 2 diabetic patients. Method: 140 elderly patients with type 2 diabetes who admitted to our hospital (age ≥ 65 years old) were screened, the serum cystatin C level of whom was measured. According to the patients’ serum cystatin C concentration, all patients were divided into the normal cystatin C group (cystatin C ≤ 1.03 mg/L) 60 cases and the higher cystatin C group (cystatin C &gt; 1.03 mg/L) 71 cases. Left ventricular ejection fraction (EF), left atrial diameter (LAD), left ventricular end-diastolic diameter (LVD), left ventricular posterior wall thickness (LVPWT), and ventricular septal thickness (IVST) were measured by echocardiography in both groups, then left ventricular mass index (LVMI) was calculated. These indexes were compared between groups, and the correlation between serum cystatin C and ventricular remodeling was analyzed. Results: Compared to the normal cystatin C group, the LVMI and IVST of the higher cystatin C group were significantly increased (P &lt; 0.01). Correlation analysis showed that serum cystatin C content was positively correlated with LVMI and IVST, and it was statistically significant (P &lt; 0.01). Conclusion: The serum cystatin C level and ventricular remodeling in elderly type 2 diabetic patients have significant correlation. Cystatin C can be used as an index to measure the degree of ventricular remodeling in elderly type 2 diabetic patients.
 
</p></abstract><kwd-group><kwd>胱抑素C，II型糖尿病，心室重构, Cystatin C</kwd><kwd> Type 2 Diabetes</kwd><kwd> Ventricular Remodeling</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨老年II型糖尿病患者血清胱抑素C与心室重构的相关性。方法：筛选就诊于我院的老年II型糖尿病患者140例(年龄均 ≥ 65岁)，检测患者血清胱抑素C浓度，根据老年II型糖尿病患者血清胱抑素C浓度，将全部患者分为胱抑素C正常组(胱抑素C ≤ 1.03 mg/L) 60例，胱抑素C升高组(胱抑素C &gt; 1.03 mg/L) 71例。使用超声心动图测量两组患者左室射血分数(left ventricular ejection fraction, EF)、左房内径(left atrial diameter, LAD)、左室舒张末内径(left ventricular end-diastolic diameter, LVD)、左室后壁厚度(left ventricular posterior wall thickness, LVPWT)、室间隔厚度(ventricular septal thickness, IVST)并计算左室质量指数(left ventricular mass index, LVMI)。对这些指标进行组间比较，并分析血清胱抑素C与心室重构的相关性。结果：与胱抑素C正常组相比，胱抑素C升高组的LVMI、IVST显著增高(P &lt; 0.01)。相关分析显示：血清胱抑素C含量与LVMI、IVST呈正相关，并具有统计学意义(P &lt; 0.01)。结论：血清胱抑素C浓度与老年II型糖尿病患者心室重构具有显著相关性，可作为衡量II型糖尿病患者心室重构程度的一项指标。</p></sec><sec id="s2"><title>关键词</title><p>胱抑素C，II型糖尿病，心室重构</p></sec><sec id="s3"><title>Correlation between Serum Cystatin C and Ventricular Remodeling in Elderly Type 2 Diabetic Patients<sup> </sup></title><p>Yu Xiao<sup>1*</sup>, Shanshan Yuan<sup>1</sup>, Ting Zhao<sup>2</sup>, Hongyan Dai<sup>1#</sup></p><p><sup>1</sup>Department of Healthcare Cardiology, Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Outpatient Programme, Affiliated Qingdao Municipal Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/56-1571844x5_hanspub.png?20211020084419292" /></p><p>Received: Dec. 28<sup>th</sup>, 2020; accepted: Jan. 21<sup>st</sup>, 2021; published: Jan. 29<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/56-1571844x6_hanspub.png?20211020084419292" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the correlation between serum cystatin C and ventricular remodeling in elderly type 2 diabetic patients. Method: 140 elderly patients with type 2 diabetes who admitted to our hospital (age ≥ 65 years old) were screened, the serum cystatin C level of whom was measured. According to the patients’ serum cystatin C concentration, all patients were divided into the normal cystatin C group (cystatin C ≤ 1.03 mg/L) 60 cases and the higher cystatin C group (cystatin C &gt; 1.03 mg/L) 71 cases. Left ventricular ejection fraction (EF), left atrial diameter (LAD), left ventricular end-diastolic diameter (LVD), left ventricular posterior wall thickness (LVPWT), and ventricular septal thickness (IVST) were measured by echocardiography in both groups, then left ventricular mass index (LVMI) was calculated. These indexes were compared between groups, and the correlation between serum cystatin C and ventricular remodeling was analyzed. Results: Compared to the normal cystatin C group, the LVMI and IVST of the higher cystatin C group were significantly increased (P &lt; 0.01). Correlation analysis showed that serum cystatin C content was positively correlated with LVMI and IVST, and it was statistically significant (P &lt; 0.01). Conclusion: The serum cystatin C level and ventricular remodeling in elderly type 2 diabetic patients have significant correlation. Cystatin C can be used as an index to measure the degree of ventricular remodeling in elderly type 2 diabetic patients.</p><p>Keywords:Cystatin C, Type 2 Diabetes, Ventricular Remodeling</p><disp-formula id="hanspub.40155-formula15"><graphic xlink:href="//html.hanspub.org/file/56-1571844x7_hanspub.png?20211020084419292"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/56-1571844x8_hanspub.png?20211020084419292" /> <img src="//html.hanspub.org/file/56-1571844x9_hanspub.png?20211020084419292" /></p></sec><sec id="s5"><title>1. 引言</title><p>胱抑素C (Cystatin C, Cys-C)是一种半胱氨酸蛋白酶抑制剂，其在临床上作为评估肾小球滤过率(glomerular filtration rate, eGFR)的一种内源性物质被广泛应用，此外，目前已有研究证实，Cys-C与心血管事件(如中风、心力衰竭、心肌梗死和心血管死亡)有较强的相关性 [<xref ref-type="bibr" rid="hanspub.40155-ref1">1</xref>]。随着我国人口老龄化及生活方式的改变，糖尿病患病率逐年升高，而糖尿病是多种心、脑血管疾病的独立危险因素 [<xref ref-type="bibr" rid="hanspub.40155-ref2">2</xref>]。因此临床上需要更积极地筛查和防治糖尿病并发的多种心血管疾病，目前Cys-C对心室重构的影响及预测作用缺乏大量的临床研究，药物控制Cys-C水平对老年II型糖尿病患者心室重构等糖尿病并发症是否有益也没有明确定论。故本次研究主要通过检测糖尿病患者血清Cys-C水平的变化并评价其与心室重构各项指标之间的关系，评估临床上Cys-C是否可以作为II型糖尿病并发心肌肥厚等心室重构的危险因素及预测因子。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>收集2020年10月至2020年12月就诊于青岛市市立医院且符合II型糖尿病诊断标准的年龄大于65岁的患者140例作为研究对象，按照血清Cys C水平高低将其分为：胱抑素C正常组(胱抑素C ≤ 1.03 mg/L) 60例，胱抑素C升高组(胱抑素C &gt; 1.03 mg/L) 71例 [<xref ref-type="bibr" rid="hanspub.40155-ref3">3</xref>]。本研究获得医院临床伦理委员会的批准，所有受试对象均知情并同意。排除标准：1) 严重肝肾功能衰竭患者；2) 库欣综合征、甲状腺功能亢进等其他内分泌系统疾病的患者；3) 恶性肿瘤患者；4) 处于妊娠期、哺乳期的患者；5) 伴有心力衰竭的患者；6) 急性感染疾病的患者；7) 免疫系统疾病患者。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><sec id="s6_2_1"><title>2.2.1. 一般资料</title><p>记录符合筛选标准的入选患者的年龄、性别、身高、体重、心率(HR)并于入院当日测量患者收缩压、舒张压。于入院第2天早晨采集空腹静脉血，于医院常规实验室检测总胆固醇(total cholesterol, TC)、甘油三酯(triglyceride, TG)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol, LDL-C)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol, HDL-C)、空腹血糖(fasting blood glucose, FBG)、糖化血红蛋白(HemoglobinA1c, HbA1c)、Cys-C水平。</p></sec><sec id="s6_2_2"><title>2.2.2. 身体质量指数(body Mass Index, BMI)测定</title><p>BMI计算公式为： BMI = 体 重 ( kg ) &#247; 身 高 ( m ) 2 。</p></sec><sec id="s6_2_3"><title>2.2.3. 超声心动图检查</title><p>由经验丰富的专科医生采用Philips公司生产的IE33彩色超声诊断仪测量左室射血分数(EF)、左房内径(LAD)、左室舒张末内径(LVD)、左室后壁厚度(LVPWT)、室间隔厚度(IVST)，上述测量均取自患者同一时间段的3个不同心动周期并求得平均值，两组患者EF值均大于55%。</p></sec><sec id="s6_2_4"><title>2.2.4. 计算左室质量指数(LVMI)</title><p>LVMI ( g / m 2 ) = 心 室 重 量 LVMg 体 表 面 积 BSAm 2 = 0.8 &#215; 1.04 [ ( IVST + LVPWT + LVD ) 3 − LVD 3 ] + 0.6 0.0061 &#215; 身 高 ( cm ) + 0.0128 &#215; 体 重 ( kg ) − 0.1529 [<xref ref-type="bibr" rid="hanspub.40155-ref4">4</xref>]。</p></sec></sec><sec id="s6_3"><title>2.3. 统计学处理</title><p>所得实验数据使用SPSS 26.0统计软件进行统计分析。计量资料用均数 &#177; 标准差( x &#175; &#177; s )表示，两组间的比较采用t检验；组间两两比较采用LSD-t检验；计数资料比较采用卡方检验；应用Pearson相关性分析分析正态分布变量之间相关性，当P &lt; 0.05时有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组一般临床资料比较</title><p>Cys-C正常组与Cys-C升高组患者的年龄、身高、体重、BMI、收缩压、舒张压、TC、TG、LDL-C、HDL-C、FBG、HbA1c值均无明显差异(P &gt; 0.05)，见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general clinical data between the two group</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数 (人)</th><th align="center" valign="middle" >年龄 (岁)</th><th align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</th><th align="center" valign="middle" >HR (次/min)</th><th align="center" valign="middle" >收缩压 (mmHg)</th><th align="center" valign="middle"  colspan="2"  >舒张压 (mmHg)</th></tr></thead><tr><td align="center" valign="middle" >Cys-C升高组</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >72.79 &#177; 5.72</td><td align="center" valign="middle" >26.39 &#177; 3.38</td><td align="center" valign="middle" >76.00 &#177; 10.28</td><td align="center" valign="middle" >147.55 &#177; 18.77</td><td align="center" valign="middle"  colspan="2"  >75.99 &#177; 12.02</td></tr><tr><td align="center" valign="middle" >Cys-C正常组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >70.67 &#177; 5.81</td><td align="center" valign="middle" >25.66 &#177; 2.74</td><td align="center" valign="middle" >77.00 &#177; 8.38</td><td align="center" valign="middle" >139.38 &#177; 20.64</td><td align="center" valign="middle"  colspan="2"  >80.85 &#177; 11.93</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.10</td><td align="center" valign="middle" >1.35</td><td align="center" valign="middle" >−0.60</td><td align="center" valign="middle" >2.37</td><td align="center" valign="middle" >−2.32</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.403</td><td align="center" valign="middle" >0.391</td><td align="center" valign="middle" >0.072</td><td align="center" valign="middle" >0.709</td><td align="center" valign="middle" >0.294</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >HDL-C (mmol/L)</th><th align="center" valign="middle" >LDL-C (mmol/L)</th><th align="center" valign="middle" >TC (mmol/L)</th><th align="center" valign="middle" >TG (mmol/L)</th><th align="center" valign="middle" >FBG (mmol/L)</th></tr></thead><tr><td align="center" valign="middle" >Cys-C升高组</td><td align="center" valign="middle" >1.00 &#177; 0.28</td><td align="center" valign="middle" >2.66 &#177; 0.90</td><td align="center" valign="middle" >4.43 &#177; 1.23</td><td align="center" valign="middle" >1.57 &#177; 0.71</td><td align="center" valign="middle" >8.73 &#177; 3.35</td></tr><tr><td align="center" valign="middle" >Cys-C正常组</td><td align="center" valign="middle" >1.11 &#177; 0.27</td><td align="center" valign="middle" >2.64 &#177; 0.78</td><td align="center" valign="middle" >4.59 &#177; 1.14</td><td align="center" valign="middle" >1.61 &#177; 1.44</td><td align="center" valign="middle" >9.34 &#177; 3.41</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >−2.40</td><td align="center" valign="middle" >0.115</td><td align="center" valign="middle" >−0.783</td><td align="center" valign="middle" >−0.194</td><td align="center" valign="middle" >−1.02</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.494</td><td align="center" valign="middle" >0.301</td><td align="center" valign="middle" >0.494</td><td align="center" valign="middle" >0.217</td><td align="center" valign="middle" >0.294</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 两组一般临床资料比较</p><p>注：BMI：身体质量指数；HR：心率；HDL-C：高密度脂蛋白胆固醇；LDL-C：低密度脂蛋白胆固醇；TC：总胆固醇；TG甘油三酯；FBG：空腹血糖。</p></sec><sec id="s7_2"><title>3.2. 两组心脏结构比较</title><p>Cys-C升高组与Cys-C正常组相比，两组间LAD、LVD、LVPWT及EF值未见明显差异(P &gt; 0.05)，而Cys-C升高组的IVST、LVMI较Cys-C正常组明显升高，差异具有统计学意义(P &lt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of cardiac structure between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >Cys-C (mg/L)</th><th align="center" valign="middle" >LAD (cm)</th><th align="center" valign="middle" >LVD (cm)</th><th align="center" valign="middle" >IVST (cm)</th><th align="center" valign="middle" >LVPWT (cm)</th><th align="center" valign="middle" >LVMI (g/m<sup>2</sup>)</th><th align="center" valign="middle" >EF %</th></tr></thead><tr><td align="center" valign="middle" >Cys-C升高组</td><td align="center" valign="middle" >2.32 &#177; 1.78</td><td align="center" valign="middle" >3.87 &#177; 0.45</td><td align="center" valign="middle" >4.57 &#177; 0.41</td><td align="center" valign="middle" >1.06 &#177; 0.17</td><td align="center" valign="middle" >0.97 &#177; 0.11</td><td align="center" valign="middle" >92.50 &#177; 21.94</td><td align="center" valign="middle" >59.82 &#177; 1.26</td></tr><tr><td align="center" valign="middle" >Cys-C正常组</td><td align="center" valign="middle" >0.77 &#177; 0.17</td><td align="center" valign="middle" >3.67 &#177; 0.42</td><td align="center" valign="middle" >4.28 &#177; 0.56</td><td align="center" valign="middle" >0.89 &#177; 0.07</td><td align="center" valign="middle" >0.89 &#177; 0.08</td><td align="center" valign="middle" >69.17 &#177; 14.02</td><td align="center" valign="middle" >59.90 &#177; 1.04</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >6.76</td><td align="center" valign="middle" >2.75</td><td align="center" valign="middle" >3.45</td><td align="center" valign="middle" >7.23</td><td align="center" valign="middle" >5.12</td><td align="center" valign="middle" >7.10</td><td align="center" valign="middle" >−0.408</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.327</td><td align="center" valign="middle" >0.801</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.325</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.054</td></tr></tbody></table></table-wrap><p>表2. 两组心脏结构比较</p><p>注：Cys C：胱抑素C；LAD：左房内径；LVD：左室舒张末内径；LVPWT：左室后壁厚度；IVST：室间隔厚度；LVMI：左室质量指数；EF：左室射血分数。</p></sec><sec id="s7_3"><title>3.3. 对II型糖尿病患者IVST及LVMI与临床检测指标的相关性分析</title><p>对II型糖尿病患者IVST、LVMI与临床指标进行Pearson相关性分析，当r &lt; 0.3时不考虑相关性。</p><p>结果显示：IVST与Cys-C、LVPWT呈正相关，相关系数为0.53、0.76，具有统计学意义(P均 &lt; 0.05)，见表3；而LVMI与Cys-C、LVD、IVST、LVPWT均呈正相关，相关系数分别为0.39、0.68、0.76、0.66，具有统计学意义(P均 &lt; 0.05)，见表4。</p><table-wrap-group id="3"><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Correlation analysis of IVST and clinical indicator</title></caption><table-wrap id="3_1"><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >r值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.12</td><td align="center" valign="middle" >0.175</td></tr><tr><td align="center" valign="middle" >身高</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >0.809</td></tr><tr><td align="center" valign="middle" >体重</td><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >0.574</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >0.06</td><td align="center" valign="middle" >0.473</td></tr><tr><td align="center" valign="middle" >收缩压</td><td align="center" valign="middle" >0.07</td><td align="center" valign="middle" >0.430</td></tr><tr><td align="center" valign="middle" >舒张压</td><td align="center" valign="middle" >−0.21</td><td align="center" valign="middle" >0.019</td></tr><tr><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >0.859</td></tr></tbody></table></table-wrap><table-wrap id="3_2"><table><tbody><thead><tr><th align="center" valign="middle" >LDL-C</th><th align="center" valign="middle" >−0.05</th><th align="center" valign="middle" >0.552</th></tr></thead><tr><td align="center" valign="middle" >TG</td><td align="center" valign="middle" >0.01</td><td align="center" valign="middle" >0.88</td></tr><tr><td align="center" valign="middle" >TC</td><td align="center" valign="middle" >−0.14</td><td align="center" valign="middle" >0.110</td></tr><tr><td align="center" valign="middle" >FBG</td><td align="center" valign="middle" >0.10</td><td align="center" valign="middle" >0.259</td></tr><tr><td align="center" valign="middle" >HDL-C</td><td align="center" valign="middle" >−0.13</td><td align="center" valign="middle" >0.130</td></tr><tr><td align="center" valign="middle" >HbA1c</td><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >0.594</td></tr><tr><td align="center" valign="middle" >LAD</td><td align="center" valign="middle" >0.24</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >Cys-C</td><td align="center" valign="middle" >0.53</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >EF</td><td align="center" valign="middle" >0.067</td><td align="center" valign="middle" >0.446</td></tr><tr><td align="center" valign="middle" >LVD</td><td align="center" valign="middle" >0.25</td><td align="center" valign="middle" >0.040</td></tr><tr><td align="center" valign="middle" >LVPWT</td><td align="center" valign="middle" >0.76</td><td align="center" valign="middle" >0.001</td></tr></tbody></table></table-wrap></table-wrap-group><p>表3. IVST与各临床指标相关性分析</p><p>注：BMI：身体质量指数；HR：心率；HDL-C：高密度脂蛋白胆固醇；LDL-C：低密度脂蛋白胆固醇；TC：总胆固醇；TG甘油三酯；FBG：空腹血糖；Cys-C：胱抑素C；LAD：左房内径；LVD：左室舒张末内径；LVPWT：左室后壁厚度；IVST：室间隔厚度；LVMI：左室质量指数；EF：左室射血分数。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Correlation analysis of LVMI and clinical indicator</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >r值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.15</td><td align="center" valign="middle" >0.085</td></tr><tr><td align="center" valign="middle" >身高</td><td align="center" valign="middle" >−0.08</td><td align="center" valign="middle" >0.341</td></tr><tr><td align="center" valign="middle" >体重</td><td align="center" valign="middle" >−0.14</td><td align="center" valign="middle" >0.113</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >−0.09</td><td align="center" valign="middle" >0.284</td></tr><tr><td align="center" valign="middle" >收缩压</td><td align="center" valign="middle" >0.07</td><td align="center" valign="middle" >0.413</td></tr><tr><td align="center" valign="middle" >舒张压</td><td align="center" valign="middle" >−0.01</td><td align="center" valign="middle" >0.984</td></tr><tr><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >−0.16</td><td align="center" valign="middle" >0.065</td></tr><tr><td align="center" valign="middle" >LDL-C</td><td align="center" valign="middle" >−0.03</td><td align="center" valign="middle" >0.759</td></tr><tr><td align="center" valign="middle" >TG</td><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.639</td></tr><tr><td align="center" valign="middle" >TC</td><td align="center" valign="middle" >−0.13</td><td align="center" valign="middle" >0.134</td></tr><tr><td align="center" valign="middle" >FBG</td><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.658</td></tr><tr><td align="center" valign="middle" >HDL-C</td><td align="center" valign="middle" >−0.10</td><td align="center" valign="middle" >0.271</td></tr><tr><td align="center" valign="middle" >HbA1c</td><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.695</td></tr><tr><td align="center" valign="middle" >LAD</td><td align="center" valign="middle" >0.25</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >Cys-C</td><td align="center" valign="middle" >0.39</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >EF</td><td align="center" valign="middle" >−0.07</td><td align="center" valign="middle" >0.426</td></tr><tr><td align="center" valign="middle" >LVD</td><td align="center" valign="middle" >0.68</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >IVST</td><td align="center" valign="middle" >0.76</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >LVPWT</td><td align="center" valign="middle" >0.66</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表4. LVMI与各临床指标相关性分析</p><p>注：BMI：身体质量指数；HR：心率；HDL-C：高密度脂蛋白胆固醇；LDL-C：低密度脂蛋白胆固醇；TC：总胆固醇；TG甘油三酯；FBG：空腹血糖；Cys-C：胱抑素C；LAD：左房内径；LVD：左室舒张末内径；LVPWT：左室后壁厚度；IVST：室间隔厚度；LVMI：左室质量指数；EF：左室射血分数。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>II型糖尿病是多种心血管疾病高危因素，临床上糖尿病患者常合并有不同程度的各种心血管疾病，其中心室重构是是慢性心力衰竭等心血管疾病的主要发病机制之一，II型糖尿病且伴有早期肾功能损害的患者易发生心室重构 [<xref ref-type="bibr" rid="hanspub.40155-ref5">5</xref>]，心室重构指心室肌重量增加、心室容量增加以及心室形状的改变，而关于伴有早期肾功能损害的糖尿病患者心室重构的具体机制仍未完全阐明。Cys-C是一种内源性半胱氨酸蛋白酶抑制剂，是溶酶体半胱氨酸蛋白酶竞争性抑制剂家族中的一员，在所有的有核细胞中以恒定的速度合成，并在肾小球内自由过滤，在近端小管被完全重吸收和分解代谢 [<xref ref-type="bibr" rid="hanspub.40155-ref6">6</xref>]，目前临床上常将血清Cys-C作为反映肾小球滤过率的理想标志物之一，近期有大量研究表明其与多种心血管疾病密切相关 [<xref ref-type="bibr" rid="hanspub.40155-ref7">7</xref>]，故我们推测Cys-C与老年II型糖尿病患者心室重构过程有关。</p><p>本次研究对老年II型糖尿病患者血清Cys-C水平与心室重构相关指标之间的关系进行了初步探索，研究结果显示：与Cys-C正常的老年II型糖尿病患者相比，Cys C升高患者的IVST及LVMI明显升高，呈现正相关关系。</p><p>近年来许多研究证实Cys-C除与肾小球滤过率密切相关外 [<xref ref-type="bibr" rid="hanspub.40155-ref8">8</xref>]，也参与心血管疾病的病理进展过程，许多学者将其作为一种在心血管疾病中有预测价值的生物标记物来重新定义 [<xref ref-type="bibr" rid="hanspub.40155-ref9">9</xref>]，其对心血管事件有很强的预测作用，并能用于高危人群的心血管疾病风险评估 [<xref ref-type="bibr" rid="hanspub.40155-ref1">1</xref>]。心室重构是心源性死亡、心律失常和心力衰竭的独立危险因素之一，目前的研究证实心室重构与心肌肥厚以及心肌纤维化相关，Xian Wu Cheng等人发现，在高血压诱导导致的左心室肥厚的心肌细胞中，Cys-C表达增加，参与心肌肥厚的发生 [<xref ref-type="bibr" rid="hanspub.40155-ref10">10</xref>]。之后，有实验证实Cys-C与心脏的向心性肥厚表现独立相关，在校正了各种传统的肾功能指标后，左心室重量、向心性心肌肥厚和室壁厚度的增加仍然与Cys-C相关，故推测Cys-C与亚临床代表向心性肥厚的指标之间的关联性可能比舒张期功能障碍出现的更早 [<xref ref-type="bibr" rid="hanspub.40155-ref11">11</xref>]。之后，2013年Xin Li等人的实验证实血清Cys-C水平与高血压患者的LVPWT、IVST及LVMI呈正相关 [<xref ref-type="bibr" rid="hanspub.40155-ref12">12</xref>]，心脏结构异常在代偿期的表现是心肌的向心性肥厚，即室间隔和左室后壁的增厚，该实验进一步证实Cys-C是心脏结构异常发生发展的预测因子之一。另外，Cys-C可能通过增加骨桥蛋白和基质蛋白抑制因子-1的积累从而促进心肌的纤维化 [<xref ref-type="bibr" rid="hanspub.40155-ref13">13</xref>]，从另一方面导致心室重构的发展。</p><p>目前对老年II型糖尿病患者Cys-C与心室重构之间关系的研究较少，本研究发现Cys-C与老年II型糖尿病患者的IVST和LVMI升高呈正相关，这与2016年姜巍娇等人的实验结果一致，该研究发现合并慢性心力衰竭的糖尿病患者血清中Cys-C与左心室重构密切相关，证实Cys-C参与了慢性心力衰竭的发生，可以用于慢性心力衰竭患者心功能的评估 [<xref ref-type="bibr" rid="hanspub.40155-ref14">14</xref>]，故我们认为Cys-C可以作为衡量老年II型糖尿病患者心室重构程度的指标之一。但本次研究过程中没有发现LVPWT与Cys-C的明确相关性，可能与本实验样本量较小有关，Cys-C与其他心室重构相关指标的相关性仍需扩大样本量后进行。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，我们的研究证实Cys-C与老年II型糖尿病患者心室重构严重程度密切相关，II型糖尿病患者出现早期肾脏损害时伴有血清中Cys-C的升高，长期Cys-C升高可能导致心室重构的发生发展，临床上可以通过动态监测患者血清中Cys-C水平来评估糖尿病患者心室重构的程度，重点关注伴有Cys-C升高的糖尿病高危人群，采取针对性措施予以干预从而减少老年II型糖尿病患者并发的心室重构和心血管疾病风险，达到改善患者的预后的目的。</p></sec><sec id="s10"><title>基金项目</title><p>青岛市医疗卫生优秀学科带头人计划(青卫科教字[<xref ref-type="bibr" rid="hanspub.40155-ref2019">2019</xref>] 9号)。</p></sec><sec id="s11"><title>文章引用</title><p>肖 瑜,苑姗姗,赵 婷,戴红艳. 老年II型糖尿病患者血清胱抑素C与心室重构的相关性Correlation between Serum Cystatin C and Ventricular Remodeling in Elderly Type 2 Diabetic Patients[J]. 临床医学进展, 2021, 11(01): 396-402. https://doi.org/10.12677/ACM.2021.111056</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40155-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Carretero, R., Vigil-Medina, L., Barquero-Perez, O., et al. (2017) Cystatin C as a Predictor of Cardiovascular Outcomes in a Hypertensive Population. Journal of Human Hypertension, 31, 801-807.  
&lt;br&gt;https://doi.org/10.1038/jhh.2017.68</mixed-citation></ref><ref id="hanspub.40155-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版) [J]. 中国实用内科杂志, 2018, 38(4): 292-344.</mixed-citation></ref><ref id="hanspub.40155-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">易小林. 血清胱抑素C检验在肾脏疾病中的临床价值[J]. 临床合理用药杂志, 2020, 13(34): 155-156.</mixed-citation></ref><ref id="hanspub.40155-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">张莉, 杨依萌, 冷吉燕, 等. 老年冠心病患者血尿酸及左室质量指数与冠状动脉病变程度的相关性[J]. 中国老年学杂志, 2017, 37(24): 6067-6069.</mixed-citation></ref><ref id="hanspub.40155-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">曹丽萍, 赵国忠, 何敏, 等. 2型糖尿病早期肾损害与心室重构的关系研究[J]. 实用预防医学, 2017, 24(5): 544-547.</mixed-citation></ref><ref id="hanspub.40155-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Taglieri, N., Koenig, W. and Kaski, J.C. (2009) Cystatin C and Cardiovascular Risk. Clinical Chemistry, 55, 1932-1943.  
&lt;br&gt;https://doi.org/10.1373/clinchem.2009.128397</mixed-citation></ref><ref id="hanspub.40155-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李拜红, 王晓彦. 血清胱抑素C对慢性心力衰竭诊断及疗效评估相关性研究[J]. 中西医结合心血管病电子杂志, 2019, 7(29): 70-76.</mixed-citation></ref><ref id="hanspub.40155-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Bargnoux, A.-S., et al. (2019) Estimation of Glomerular Filtration Rate Using Cystatin C. Annales de Biologie Clinique, 77, 375-380. &lt;br&gt;https://doi.org/10.1684/abc.2019.1456</mixed-citation></ref><ref id="hanspub.40155-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Mallikethi-Reddy, S., Briasoulis, A., Akintoye, E., et al. (2017) Novel Biomarkers with Potential for Cardiovascular Risk Reclassification. Biomarkers, 22, 1-32. &lt;br&gt;https://doi.org/10.1080/1354750X.2016.1201540</mixed-citation></ref><ref id="hanspub.40155-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, X.W., Obata, K., Kuzuya, M., et al. (2006) Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure. Hypertension, 48, 979-987.  
&lt;br&gt;https://doi.org/10.1161/01.HYP.0000242331.99369.2f</mixed-citation></ref><ref id="hanspub.40155-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Balko, J.A., Gupta, S., Mammen, P.P.A., et al. (2009) Association of Cystatin C with Left Ventricular Structure and Function: The Dallas Heart Study. Circulation Heart Failure, 2, 98.  
&lt;br&gt;https://doi.org/10.1161/CIRCHEARTFAILURE.108.807271</mixed-citation></ref><ref id="hanspub.40155-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Zhu, H., Li, P., et al. (2013) Serum Cystatin C Concentration as an Independent Marker for Hypertensive Left Ventricular Hypertrophy. Journal of Geriatric Cardiology, 10, 286-290.</mixed-citation></ref><ref id="hanspub.40155-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">何芳, 田国平. 血清胱抑素C与慢性心力衰竭的研究进展[J]. 西南军医, 2019, 21(2): 150-153.</mixed-citation></ref><ref id="hanspub.40155-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">姜巍娇, 焦凯, 李春峰, 等. 糖尿病慢性心力衰竭患者血清胱抑素C水平与心室重构的相关性研究[J]. 糖尿病新世界, 2016, 19(24): 12-13.</mixed-citation></ref></ref-list></back></article>